BCYC Quote, Financials, Valuation and Earnings

Autolus Therapeutics PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of -95193.1%. Bicycle Therapeutics PLC's return on equity of -28.27% beat Autolus Therapeutics PLC's return on equity of -51.91%.

Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 221.18%. On the other hand Autolus Therapeutics PLC has an analysts' consensus of $9.97 which suggests that it could grow by 638.27%. Given that Autolus Therapeutics PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Autolus Therapeutics PLC is more attractive than Bicycle Therapeutics PLC.

Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison Autolus Therapeutics PLC has a beta of 1.767, suggesting its more volatile than the S&P 500 by 76.723%.

Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Autolus Therapeutics PLC pays out -- of its earnings as a dividend.

Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Autolus Therapeutics PLC quarterly revenues of $29K. Bicycle Therapeutics PLC's net income of -$60.8M is lower than Autolus Therapeutics PLC's net income of -$27.6M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Autolus Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.62x versus -- for Autolus Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Biodexa Pharmaceuticals PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -28.27% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.

Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 221.18%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.94 which suggests that it could grow by 1172.62%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Bicycle Therapeutics PLC.

Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.154, suggesting its more volatile than the S&P 500 by 15.371%.

Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend.

Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than Biodexa Pharmaceuticals PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$60.8M is higher than Biodexa Pharmaceuticals PLC's net income of --. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.62x versus 1.47x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.

NuCana PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of --. Bicycle Therapeutics PLC's return on equity of -28.27% beat NuCana PLC's return on equity of --.

Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 221.18%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 100969%. Given that NuCana PLC has higher upside potential than Bicycle Therapeutics PLC, analysts believe NuCana PLC is more attractive than Bicycle Therapeutics PLC.

Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison NuCana PLC has a beta of 1.639, suggesting its more volatile than the S&P 500 by 63.921%.

Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend.

Bicycle Therapeutics PLC quarterly revenues are $10M, which are larger than NuCana PLC quarterly revenues of --. Bicycle Therapeutics PLC's net income of -$60.8M is lower than NuCana PLC's net income of -$836.1K. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.62x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.

Verona Pharma PLC has a net margin of -608.94% compared to Bicycle Therapeutics PLC's net margin of -21.4%. Bicycle Therapeutics PLC's return on equity of -28.27% beat Verona Pharma PLC's return on equity of -85.84%.

Bicycle Therapeutics PLC has a consensus price target of $26.27, signalling upside risk potential of 221.18%. On the other hand Verona Pharma PLC has an analysts' consensus of $94.10 which suggests that it could grow by 42.02%. Given that Bicycle Therapeutics PLC has higher upside potential than Verona Pharma PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Verona Pharma PLC.

Bicycle Therapeutics PLC has a beta of 1.599, which suggesting that the stock is 59.85% more volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.206, suggesting its less volatile than the S&P 500 by 79.434%.

Bicycle Therapeutics PLC has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bicycle Therapeutics PLC pays -- of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend.

Bicycle Therapeutics PLC quarterly revenues are $10M, which are smaller than Verona Pharma PLC quarterly revenues of $76.3M. Bicycle Therapeutics PLC's net income of -$60.8M is lower than Verona Pharma PLC's net income of -$16.3M. Notably, Bicycle Therapeutics PLC's price-to-earnings ratio is -- while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bicycle Therapeutics PLC is 20.62x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.